This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
Introduction In todays hyper-competitive healthcare space, building a Lead Generation Network in pharma is no longer optionalits essential. Much like a clinical trial needs carefully selected participants, pharma marketers must construct targeted networks to generate high-quality leads. But how does one translate an abstract marketing concept into a practical strategy that complies with strict regulatory frameworks while producing measurable outcomes?
Consistent adherence to pulmonary hypertension-specific oral therapy significantly improves clinical outcomes, according to a new prospective study evaluating patients with pulmonary arterial hypertension (PAH) and distal chronic thromboembolic pulmonary hypertension (CTEPH). These two conditions are progressive, life-limiting diseases where timely, consistent medication use is critical to stabilise symptoms and prolong survival.
In my work as a consultant pharmacist (which I love!), I write recommendations to nurses and providers of long term care and assisted living facilities. I wanted to share some of the most recent recommendations I’ve found that can help you identify potential drug therapy problems in your practice. If you are looking for more […] The post Recommendations in Long Term Care – 5 Recent Examples appeared first on Med Ed 101.
Prednisone is a type of medication called an oral corticosteroid. Its used to treat inflammation in the body, from conditions like allergies, asthma, arthritis, blood disorders, cancer, autoimmune diseases, and various skin conditions. Prednisone can also be used to calm an overactive immune system. If you are dealing with an itchy, uncomfortable case of poison ivy , you might be wondering if you can use prednisone for poison ivy.
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
Introduction When was the last time a glossy pharma ad truly resonated with a patient living with chronic illness? In today’s healthcare marketing landscape, trust is the new currencyand real stories matter more than polished commercials. Thats why Influencer Marketing In Pharma is gaining momentum as a critical tool for reaching audiences in a more authentic, impactful way.
As the NHS advances, effective clinical leadership in pharmacy is vital to improve the pharmaceutical care of patients. In Scotland, the Scottish Pharmacy Clinical Leadership Fellowship scheme aims to support just that, as Gerry Hughes finds out. The goal of the Scottish Pharmacy Clinical Leadership Fellowship , launched in 2018, is to nurture future pharmacy leaders and advance strategic healthcare goals in Scotland.
The era of “tranq” may be ending. But tranq, as the powerful veterinary tranquilizer xylazine is known in the illicit drug supply, is being replaced at least in part by a dangerous new sedative: medetomidine. In the past year, the anesthetic has become an increasingly common element in the drug supply, with cities and states including Philadelphia, Pittsburgh, Chicago, and San Francisco reporting cases of medetomidine-involved overdoses.
Signup to get articles personalized to your interests!
Pharmacy Technician Pulse brings together the best content for pharmacy technicians from the widest variety of industry thought leaders.
The era of “tranq” may be ending. But tranq, as the powerful veterinary tranquilizer xylazine is known in the illicit drug supply, is being replaced at least in part by a dangerous new sedative: medetomidine. In the past year, the anesthetic has become an increasingly common element in the drug supply, with cities and states including Philadelphia, Pittsburgh, Chicago, and San Francisco reporting cases of medetomidine-involved overdoses.
Ozempic (semaglutide) is a glucagon-like peptide-1 receptor agonist, or GLP-1. It was originally approved by the U.S. Food and Drug Administration (FDA) in 2017 to help people with Type 2 diabetes manage their blood sugar levels. The injectable drug’s popularity soared when it was discovered that weight loss was an added bonus. Eventually, the FDA also approved another form of semaglutide , Wegovy , specifically for weight management.
Introduction Imagine standing at the edge of a revolution, where every tool you need to succeed is finally within reach. That’s precisely where pharmaceutical marketers find themselves today. Pharma marketing innovation is poised for an unprecedented surge in 2025, driven by new technologies, regulatory shifts, and evolving patient expectations.
The US Pharmacopeia (USP) has launched a selection of resources, including reference materials and standards, to support developers and manufacturers of AAV-based gene therapies. Alongside these resources, USP is publishing the proposed General Chapter <1067> AAV Best Practices for the Manufacture and Quality Control of Recombinant Adeno-Associated Virus (rAAV) Gene Therapy Products.
For the second consecutive year, the pharmaceutical industry saw its reputation slip among patient advocacy groups, largely due to ongoing concerns over pricing issues, according to a new survey. Of more than 2,500 groups queried, 56% reported the industry had an “excellent” or “good” reputation as it goes about the business of developing and providing medicines.
Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.
Semaglutide , sold as brand names Ozempic, Wegovy, and Rybelsus, is a prescription medication approved by the U.S. Food and Drug Administration (FDA) to improve blood glucose control in type 2 diabetes mellitus or for weight management. It works by enhancing insulin secretion, which slows gastric emptying, leading to decreased appetite and weight loss.
Introduction Is traditional advertising losing its edge in the pharmaceutical world? As the industry shifts toward data-driven strategies, the power of audience targeting continues to redefine how brands connect with healthcare professionals (HCPs) and patients. While print ads, radio spots, and mass media campaigns once dominated, the ability to reach the right person at the right time through digital channels has quickly taken the lead.
Should You Keep Compounding GLP1s (Tirzepatide or Semaglutide) After the FDA Deadline? Here’s My Take. Howdy pharmacy peeps… Lets have a real talk about compounding GLP1s. Theres been a lot of chatter lately in the pharmacy worldforums, Facebook groups, emails, even conference hallwaysabout whether pharmacies should keep compounding GLP1s tirzepatide/semaglutide once the FDA deadlines pass.
The explosion of compounded GLP-1 offerings over the past two years is coming to an end, and many patients are left with no good options. Blockbuster obesity and diabetes drugs — such as Wegovy, Ozempic, and Mounjaro — are no longer deemed by regulators to be in shortage, so compounding pharmacies and the telehealth companies they work with must stop offering copies of the treatments.
Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist
What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.
There is a common misconception that antibiotics can treat vaginal yeast infections, despite being primarily intended for certain types of bacterial infections. However, this medication can trigger the overgrowth of yeast, which is why antifungals are the recommended medications for treating yeast infections. Can antibiotics treat yeast infections? No, antibiotics cannot treat vaginal yeast infections.
Novartis AG has agreed to acquire the biopharmaceutical company Regulus Therapeutics Inc. This deal has potential total equity value of up to approximately $1.7 billion. It involves supporting advancement of Regulus’ lead product candidate, farabursen (RGLS 8429), a microRNA-17 (miR-17) inhibitor being developed to treat autosomal dominant polycystic kidney disease (ADPKD).
Getting ready for your board exam is a big step in your professional career. While the pressure to do well can be intense, having the right strategy and study resources is key. Following a six-month study plan will help you cover all the essential material while you build your confidence for exam day. Why Should You Study for 6 Months? Between work and other responsibilities, you likely have enough to do without worrying about preparing for your board exams.
After 15 years, the Affordable Care Act (ACA) has survived its share of challenges at the Supreme Court. On April 21, I attended the court’s first hearing in the latest of the series of ACA challenges, Kennedy v. Braidwood, which is focused on the ACA’s preventive services coverage requirement. I proudly represented 20 HIV advocacy organizations as amici in the case , urging the court to uphold the law, which requires payer coverage of items and
Are you still using workarounds to manage your daily operations? To achieve peak performance, it's time to explore other options for specialty and infusion pharmacy software. Streamline pharmacy operations and improve clinical performance with automated processing, real-time data exchange, and electronic decision support. Download this helpful infographic to: Drive efficiency and patient adherence from referral receipt to delivery and ongoing care – all with our Pharmacy Cloud.
Cequa is a prescription eye drop used in the treatment of dry eye disease. The ophthalmic solution has an immune-suppressing active ingredient, cyclosporine. For those suffering from dry eye symptoms, such as redness, irritation, burning, blurred vision, and light sensitivity, Cequa can provide welcome relief if other treatment measures are ineffective.
Table of Contents Understanding the Pharma Research Landscape Leveraging Patient Influencers in Research Utilizing Digital Tools and Platforms Strategic Steps to Initiate Pharma Research Conclusion FAQs Understanding the Pharma Research Landscape Embarking on pharma research can seem daunting, especially with the industry’s rapid evolution. However, understanding the current landscape is crucial for effective marketing strategies.
The EU has granted marketing authorisation (MA) for Filspari CSL Vifor and Travere Therapeutics therapy for primary IgA nephropathy (IgAN), a rare kidney disease advancing the ability to administer the therapy to patients globally. Filspari is a dual endothelin angiotensin receptor antagonist(DEARA), a non-immunosuppressive therapy for the treatment of IgAN.
As a professor of physiology, I study how scientific evidence gets translated, sometimes clumsily, from the lab to real life. Whether it’s scaling dietary supplements to humans or using biomimicry to mitigate sports concussion , my work often centers on the fine line between meaningful evidence and misleading extrapolation. That’s why I was immediately skeptical when the Food and Drug Administration announced its decision to ban synthetic food dyes like the controversial red dye No
When I returned to Oswalds Pharmacy in 2016, one of the first things I did was sit down with my grandparents, Bob and Jean Andersonthe fourth-generation owners of the business. Theyve lived in the same Naperville home that my great-great-great-grandfather, William Wallace Wickel, built back in 1892. Its a house filled with stories even if some are a little fuzzy.
Panelists discuss how statin therapy for primary prevention requires careful consideration of cardiovascular risk factors against potential adverse effects such as myalgia and liver abnormalities, generally favoring treatment when the calculated 10-year atherosclerotic cardiovascular disease [ASCVD] risk exceeds 7.5% to10% and adjusting recommendations based on individual patient factors including age, comorbidities, and preferences.
New research has revealed that some of the UKs most deadly and prevalent cancers receive the least amount of charitable funding, raising urgent questions about how awareness and fundraising priorities are set. The study, released by Jude, a leading bladder cancer charity, found that bladder cancer, despite being one of the most common and deadly […] The post Deadly cancers are being financially left behind, new research claims appeared first on Pharmafile.
Shares of Eli Lilly dropped in pre-market trading Thursday, as competitor Novo Nordisk secured a major win on insurance coverage of its obesity drug and as Lilly reported first-quarter earnings that fell short of what investors wanted to see. CVS Caremark, the largest pharmacy benefit manager in the U.S., announced Thursday that starting in July, Novo’s weight loss treatment Wegovy will be the preferred GLP-1 medicine on its largest commercial formularies, likely making Wegovy more access
Over the next few years, there are virtually no aspects of pharmaceutical manufacturing processes that will not be changed by artificial intelligence (AI). By harnessing AIs capabilities to analyse complex datasets, identify subtle patterns and make precise predictions, biopharmaceutical manufacturers will be able to achieve unprecedented levels of process optimisation, quality assurance and operational efficiency.
Swedish biotech company Neogap Therapeutics has been chosen to join Innovate Nordics 2025 acceleration programme, a prestigious initiative designed to help Nordic growth companies expand into the US market. Organised by the Swedish-American Chamber of Commerce in New York (SACCNY) in partnership with EY, the programme provides selected companies with access to US investor networks, […] The post Neogap chosen for Innovate Nordics 2025 Acceleration Programme appeared first on Pharmafile.
BridgeBio’s recently approved heart drug brought in $36.7 million in sales in the first quarter, blowing past expectations as the biotech continues to see a strong demand for its first major commercial product. Analysts had estimated that the treatment, called Attruby, would bring in sales of $12 million, but Wall Street’s “whisper number” was $17 million to $20 million.
Limbic's Intake Agent responds to patients in real-time and can field an unlimited number of calls, freeing up the workload on overburdened call center staff. It aims to help streamline patient intake.
Gifthealth, a technology-driven pharmacy care company, has appointed Chip Parkinson as its new chief executive officer. The move marks a strategic step in accelerating the companys mission to improve prescription efficiency and accessibility through its digital platform. Parkinson brings over three decades of leadership experience across biotech, pharmacy benefit management, diagnostics and pharma industries.
Input your email to sign up, or if you already have an account, log in here!
Enter your email address to reset your password. A temporary password will be e‑mailed to you.
We organize all of the trending information in your field so you don't have to. Join 5,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content